189 related articles for article (PubMed ID: 18618737)
1. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G
Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA
Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
Yardley DA; Burris HA; Markus T; Spigel DR; Greco FA; Mainwaring M; Waterhouse DM; Webb CD; Hainsworth JD
Clin Breast Cancer; 2009 Nov; 9(4):237-42. PubMed ID: 19933079
[TBL] [Abstract][Full Text] [Related]
9. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
12. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Mathew P; Thall PF; Bucana CD; Oh WK; Morris MJ; Jones DM; Johnson MM; Wen S; Pagliaro LC; Tannir NM; Tu SM; Meluch AA; Smith L; Cohen L; Kim SJ; Troncoso P; Fidler IJ; Logothetis CJ
Clin Cancer Res; 2007 Oct; 13(19):5816-24. PubMed ID: 17908974
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).
Alberts DS; Liu PY; Wilczynski SP; Jang A; Moon J; Ward JH; Beck JT; Clouser M; Markman M
Int J Gynecol Cancer; 2007; 17(4):784-8. PubMed ID: 17343607
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA
Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362
[TBL] [Abstract][Full Text] [Related]
16. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
18. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
Posadas EM; Kwitkowski V; Kotz HL; Espina V; Minasian L; Tchabo N; Premkumar A; Hussain MM; Chang R; Steinberg SM; Kohn EC
Cancer; 2007 Jul; 110(2):309-17. PubMed ID: 17559139
[TBL] [Abstract][Full Text] [Related]
19. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
